Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989510 | 0.78 | KMT2A (0.70) | KMT2AMEN1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL5553255 | 0.77 | KMT2A (0.54) | KMT2AMEN1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL9832661 | 0.75 | KMT2A (0.52) | KMT2AMEN1SIGMAR1ALDH1A1OPRM1 | |
| SCHEMBL16579976 | 0.73 | KMT2A (0.78) | KMT2AMEN1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL15962261 | 0.72 | SIGMAR1 (0.61) | KMT2AMEN1SIGMAR1LMNADRD4 | |
| SCHEMBL6745218 | 0.72 | SIGMAR1 (0.61) | KMT2AMEN1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL10967640 | 0.71 | LMNA (0.55) | KMT2AMEN1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL546987 | 0.71 | MEN1 (0.49) | KMT2AMEN1SIGMAR1 | |
| SCHEMBL5395547 | 0.71 | ALDH1A1 (0.56) | KMT2AMEN1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL2408307 | 0.71 | SIGMAR1 (0.55) | KMT2AMEN1SIGMAR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281133-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-11-12 | — | — | US | disclosed |
| US-20090093501-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281133-A1 | Heterocyclic antiviral compounds | CCR5, CCR1, CCR2 | KMT2A 3845/4885MEN1 4203/4885SIGMAR1 18/4885 |
| US-20090093501-A1 | Heterocyclic antiviral compounds | CCR5, CCR1, CCR2 | KMT2A 3635/4885MEN1 4450/4885SIGMAR1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.